Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

(Vidaza) in patients with Myelodysplastic Syndromes (MDS) - R. Lyons; Abstract #7083; June 2, 2007; 8am-12pm; McCormick Place Convention Center, S Hall A2)

Interim results from a Phase II, multi-center, open-label trial comparing three alternate dosing schedules of Azacitidine (AZA) in patients with MDS were presented in a poster session on Saturday, June 2. Patients were randomized to one of three regimens that were repeated every four weeks: AZA 5-2-2 (75 mg/m2/day x 5 days, two days off therapy, two additional days at same dose as the first five days); AZA 5-2-5 (50 mg/m2/day x 5 days, followed by 2 days off therapy and five additional days at the same dose as the first five days); and AZA 5 (75 mg/m2/day x 5 days).

Of 122 patients who had received two or more cycles of therapy at the time of evaluation, 61 percent experienced hematologic improvement (HI), defined as major or minor in at least one cell line. This reflects HI of 53, 70 and 60 percent in the AZA 5-2-2, AZA 5-2-5, and AZA 5 arms, respectively.

Across each of the three alternative dose regimens, 65 percent to 80 percent of patients who were red blood cell (RBC) transfusion dependent at baseline achieved transfusion independence. Comparable beneficial effects on transfusions were demonstrated in all patients and in low-risk patients for both RBCs and platelets.

To determine whether response/improvement can be maintained after six cycles, the study includes a 12 month maintenance period, in which patients are re-randomized to one of two arms: AZA 5 every four weeks or AZA 5 every six weeks. Ten patients have completed 18 treatment cycles.

These data indicate that the three alternative azacitidine dosing schedules have safety and efficacy profiles consistent with the FDA-approved regimen. Alternate dosing schedules may offer patients and clinicians a more convenient schedule by eliminating weekend treatments. Vidaza was the first demethylating agent to be approved by
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...
(Date:12/16/2009)... Naurex Inc., a new clinical stage ... CNS disorders based on its novel GFPA NMDA ... a Phase I clinical trial of its lead ... subjects in the study. GLYX-13, a glycine ... the NMDA receptor, is initially being developed as ...
(Date:12/16/2009)... Texas, Dec. 16 Savara, Inc., an inhalation ... the second tranche in its Series A financing round, ... ,, Funds raised in the Series A ... the NanoCluster technology. ,, "We now have the ... performance of the NanoCluster technology," said Rob Neville, CEO ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2Solon Manufacturing Company Acquires PurFybr Brands 3B Adds Influenza Virus Diagnostic Swabs to Product Line 12710 1Solon Manufacturing Company Acquires PurFybr Brands 3B Adds Influenza Virus Diagnostic Swabs to Product Line 12710 2Pesticide Residue Common on Kitchen Floors 49522 1Pesticide Residue Common on Kitchen Floors 49522 2Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 1Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 2Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 3Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 4
(Date:12/16/2009)... pinpoint seven that increase susceptibility to disease , , ... associated with increased susceptibility to leprosy have been ... The researchers, who analyzed more than 10,000 DNA ... China, said their discovery highlights the important role ... development of leprosy. , "Though leprosy is not ...
(Date:12/16/2009)... The omega-3 essential fatty acids commonly found ... sensory overload, according to research published by the ... to the information-processing problems found in people with ... disease; and other afflictions of the nervous system. ... Behavioral Neuroscience , provides more evidence that ...
(Date:12/16/2009)... global leader of Digital Pen and Paper technology and the ... trials, today announced that it is ranked among the Fastest ... EMEA 2009. , ... (PRWEB) December ... solutions for the capture, digitalization and management of handwritten data. ...
(Date:12/16/2009)... all-time low, government report shows, , , WEDNESDAY, Dec. 16 ... States has reached almost 78 years, a record high, ... 2007, women can expect to live to 80.4 years ... the report from the U.S. Centers for Disease Control ... expect to live longer than their parents, life expectancy ...
(Date:12/16/2009)... New research published online, December ... pistachios, and molecules present in pistachios, have ... levels of an inflammatory marker known as ... Inflammation is a complex biological response to ... and it underlies functional changes associated with ...
Breaking Medicine News(10 mins):Health News:Leprosy Genes Identified 2Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3
... June 5 Soaring gas prices are,a contributing factor ... on,the poorest and most vulnerable within the global community ... situation is particularly devastating in Ethiopia, one of the ... in 2007 and again in 2008,compounded the Ethiopian situation, ...
... ) today reported preliminary total retail drug,store sales for the four-week and seventeen-week periods ended May 29,2008., ... Periods ended May 29, 2008 ... Month Year to Date (Dollars ... (4 weeks) (17 weeks), Total retail drug store sales ...
... A Closer Look at The Value of,MRIs ... of,America,s (MSAA) website, http://www.msassociation.org . This three ... offering a first-hand,account on the experience of undergoing ... well as the importance of MRIs to monitor ...
... Benchmarking is not a luxury;,it is an activity that ... a survey analysis of 30 companies and in-depth interviews,with ... benchmarking in a,difficult economy., The complete study addresses ... the goals of benchmarking studies, how companies are,demonstrating value ...
... Forum to Explore Solutions Presented by The Massachusetts ... 5 "We are greatly,concerned in this state about ... of our returning veterans, the stress, depression and ... specter of rising levels of,domestic violence and suicide. ...
... entertainment and ... more, ... fitness and figure competitors Allison,Frahn and Tina Durkin, will represent GNC at ... Centre in Atlanta., Chad, part of the World Natural Bodybuilding Federation ...
Other Medicine News:Health News:Impact of Rising Gas, Food Prices Felt Globally 2Health News:Longs Reports Preliminary May Retail Drug Store Sales 2Health News:Photos: The Multiple Sclerosis Association of America Produces a Web Video on the Importance of MRIs 2Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:Rite Aid Health and Beauty Expo to Showcase GNC Athletes 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: